The most widely used COVID-19 vaccines may offer a surprise benefit for some cancer patients – revving up their immune systems to help fight tumors.
The most widely used COVID-19 vaccines may offer a surprise benefit for some cancer patients – revving up their immune systems to help fight tumors.
People with advanced lung or skin cancer who were taking certain immunotherapy drugs lived substantially longer if they also got a Pfizer or Moderna shot within 100 days of starting treatment, according to preliminary research being reported Wednesday in the journal Nature.
And it had nothing to do with virus infections.
Instead, the molecule that powers those specific vaccines, mRNA, appears to help the immune system respond better to the cutting-edge cancer treatment, concluded researchers from MD Anderson Cancer Center in Houston and the University of Florida.
The vaccine “acts like a siren to activate immune cells throughout the body,” said lead researcher Dr. Adam Grippin of MD Anderson. “We’re sensitizing immune-resistant tumors to immune therapy.”
Health Secretary Robert F. Kennedy Jr. has raised skepticism about mRNA vaccines, cutting $500 million in funding for some uses of the technology.
But this research team found its results so promising that it is preparing a more rigorous study to see if mRNA coronavirus vaccines should be paired with cancer drugs called checkpoint inhibitors — an interim step while it designs new mRNA vaccines for use in cancer.
